Obesity exacerbates chemically induced neurodegeneration

Neuroscience

Volumn 115, Issue 4, 2002, Pages 1335-1346

  Sriram, K ^a   Benkovic, S A ^a   Miller, D B ^a   O'Callaghan, J P ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Brain; Glial fibrillary acidic protein; Kainic acid; Methamphetamine; Mitochondrial dysfunction; Oxidative stress

Indexed keywords

DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; KAINIC ACID; METHAMPHETAMINE; MICROTUBULE ASSOCIATED PROTEIN 2; MITOCHONDRIAL UNCOUPLING PROTEIN 2; NEUROTOXIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; GLIOSIS; HIPPOCAMPUS; IMMUNOREACTIVITY; MORTALITY; MOUSE; MOUSE STRAIN; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; RISK FACTOR; STAINING; UPREGULATION;

ANIMALS; ASTROCYTES; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; ION CHANNELS; KAINIC ACID; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; MICE; MICE, OBESE; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIAL PROTEINS; NEOSTRIATUM; NEURODEGENERATIVE DISEASES; NEURONS; NEUROTOXICITY SYNDROMES; NEUROTOXINS; OBESITY; PRESYNAPTIC TERMINALS; PROTEINS;

EID: 0037121675     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00306-8     Document Type: Article

References (62)

1. Ahima R.S., Bjorbaek C., Osei S., Flier J.S. Regulation of neuronal and glial proteins by leptin: implications for brain development. Endocrinology. 140:1999;2755-2762.
2. Arias C., Arrieta I., Massieu L., Tapia R. Neuronal damage and MAP2 changes induced by the glutamate transport inhibitor dihydrokainate and by kainate in rat hippocampus in vivo. Exp. Brain Res. 116:1997;467-476.
3. Beal M.F. Aging, energy and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
4. Behl C., Lezoualc'h F., Trapp T., Widmann M., Skutella T., Holsboer F. Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology. 138:1997;101-106.
5. Bruce-Keller A.J., Umberger G., McFall R., Mattson M.P. Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann. Neurol. 45:1999;8-15.
6. Carro E., Nunez A., Busiguina S., Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J. Neurosci. 20:2000;2926-2933.
7. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
8. Cleeter M.W., cooper J.M., Schapira A.H. Nitric oxide enhances MPP(+) inhibition of complex I. FEBS Lett. 504:2001;50-52.
9. Corcoran G.B., Wong B.K. Obesity as a risk factor in drug-induced organ injury: increased liver and kidney damage by acetaminophen in the obese overfed rat. J. Pharmacol. Exp. Ther. 241:1987;921-927.
10. Corcoran G.B., Salazar D.E., Chan H.H. Obesity as a risk factor in drug-induced organ injury: III. Increased liver and kidney injury by furosemide in the obese overfed rat. Toxicol. Appl. Pharmacol. 98:1989;12-24.
11. Dabbeni-Sala F., Floreani M., Franceschini D., Skaper S.D., Guisti P. Kainic acid induces selective mitochondrial oxidative phosphorylation enzyme dysfunction in cerebellar granule neurons: protective effects of melatonin and GSH ethyl ester. FASEB J. 15:2001;1786-1788.
12. Deng X., Cadet J.L. Methamphetamine administration causes overexpression of nNOS in the mouse striatum. Brain Res. 851:1999;254-257.
13. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389.
14. Ding M., Haglid K.G., Hamberger A. Quantitative immunochemistry on neuronal loss, reactive gliosis and BBB damage in cortex/striatum and hippocampus/amygdala after systemic kainic acid administration. Neurochem. Int. 36:2000;313-318.
15. Duan W., Mattson M.P. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. Res. 57:1999;195-206.
16. Fukumura M., Cappon G.D., Pu C., Broening H.W., Vorhees C.V. A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 806:1998;1-7.
17. Fumagalli F., Gainetdinov R.R., Valenzano K.J., Caron M.G. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 18:1998;4861-4869.
18. Gluck M.R., Jayatilleke E., Shaw S., Rowan A.J., Haroutunian V. CNS oxidative stress associated with the kainic acid rodent model of experimental epilepsy. Epilepsy Res. 39:2000;63-71.
19. Gluck, M.R., Jayatilleke, E., Meleties, P., Magliozzo, R., Manzino, L., Sonsalla, P.K., 2001. Inhibition of mitochondrial complex I by methamphetamine and its congeners. Soc. Neurosci. Abstr.
20. Gramsbergen J.B., van den Berg K.J. Regional and temporal profiles of calcium accumulation and glial fibrillary acidic protein levels in rat brain after systemic injection of kainic acid. Brain Res. 667:1994;216-228.
21. Grootendorst J., Mulder M., Haasdijk E., de Kloet E.R., Jaarsma D. Presence of apolipoprotein E immunoreactivity in degenerating neurones of mice is dependent on the severity of kainic acid-induced lesion. Brain Res. 868:2000;165-175.
22. Hatzinger M., Z'Brun A., Hemmeter U., Seifritz E., Baumann F., Holsboer-Trachsler E., Heuser I.J. Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. Neurobiol. Aging. 16:1995;205-209.
23. Hess A., Desiderio C., McAuliffe W.G. Acute neuropathological changes in the caudate nucleus caused by MPTP and methamphetamine: immunohistochemical studies. J. Neurocytol. 19:1990;338-342.
24. Hirata H., Cadet J.L. Kainate-induced hippocampal DNA damage is attenuated in superoxide dismutase transgenic mice. Brain Res. Mol. Brain Res. 48:1997;145-148.
25. Imam S.Z., Crow J.P., Newport G.D., Islam F., Slikker W. Jr., Ali S.F. Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: protective effects of peroxynitrite decomposition catalyst. Brain Res. 837:1999;15-21.
26. Ingram D.K., Weindruch R., Spangler E.L., Freeman J.R., Walford R.L. Dietary restriction benefits learning and motor performance of aged mice. J. Gerontol. 42:1987;78-81.
27. Jin T., Nordberg G.F., Sehlin J., Leffler P., Wu J. The susceptibility of spontaneously diabetic mice to cadmium-metallothionein nephrotoxicity. Toxicology. 89:1994;81-90.
28. Kaplan N.M. The deadly quartet: Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 149:1989;1514-1520.
29. Kita T., Shimada K., Mastunari Y., Wagner G.C., Kubo K., Nakashima T. Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology. 39:2000;399-406.
30. Kogan F.J., Nichols W.K., Gibb J.W. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36:1976;363-371.
31. Kuno T., Hozumi M., Morinobu T., Murata T., Mingci Z., Tamai H. Antioxidant vitamin levels in plasma and low density lipoprotein of obese girls. Free Radic. Res. 28:1998;81-86.
32. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
33. Liang L.P., Ho Y.S., Patel M. Mitochondrial superoxide production in kainite-induced hippocampal damage. Neuroscience. 101:2000;563-570.
34. Logroscino G., Marder K., Cote L., Tang M.X., Shea S., Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann. Neurol. 39:1996;89-94.
35. Mayeux R., Costa R., Bell K., Merchant C., Tang M.X., Jacobs D. Reduced risk of Alzheimer's disease among individuals with low calorie intake. Neurology. 59:1999;S296-S297.
36. McIntosh L.J., Hong K.E., Sapolsky R.M. Glucocorticoids may alter antioxidant enzyme capacity in the brain: baseline studies. Brain Res. 791:1998;209-214.
37. Miller D.B., O'Callaghan J.P. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270:1994;752-760.
38. Mizuno Y., Sone N., Saitoh T. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in electron transport system in mouse brain. J. Neurochem. 48:1987;1787-1793.
39. Mizuno Y., Ikebe S., Hattori N., Kondo T., Tanaka M., Ozwa T. Mitochondrial energy crisis in Parkinson's disease. Adv. Neurol. 60:1993;282-287.
40. National Task Force on Prevention, 2000. Overweight, obesity and health risk. Arch. Intern. Med. 160, 898-904.
41. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
42. O'Callaghan J.P., Brinton R.E., McEwen B.S. Glucocorticoids regulate the concentration of glial fibrillary acidic protein throughout the brain. Brain Res. 494:1989;159-161.
43. O'Callaghan J.P. Quantification of glial fibrillary acidic protein: comparison of slot-immunobinding assays with a novel sandwich ELISA. Neurotoxicol. Teratol. 13:1991;275-281.
44. O'Callaghan J.P., Brinton R.E., McEwen B.S. Glucocorticoids regulate the synthesis of glial fibrillary acidic protein in intact and adrenalectomized rats but do not affect its expression following brain injury. J. Neurochem. 57:1991;860-869.
45. O'Callaghan J.P., Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270:1994;741-751.
46. O'Callaghan J.P., Imai H., Miller D.B., Minter A. Quantitative immunoblots of proteins from brain homogenates: Underestimation of specific protein concentration and of treatment effects. Anal. Biochem. 274:1999;18-26.
47. O'Callaghan, J.P., 2002. Measurement of glial fibrillary acidic protein. In: Costa, L.G. (Ed.), Current Protocols in Toxicology. Wiley, New York, pp. 12.8.11-12.8.12.
48. O'Callaghan, J.P., Miller, D.B., 2002. Neurotoxic effects of substituted amphetamines in rats and mice: Challenges to the current dogma. In: Massaro, E., Broderick, P.A. (Eds.), Handbook of Neurotoxicity, vol. 2, Humana Press, Totowa, NJ, pp. 269-301.
49. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32:1972;281-294.
50. Russo-Neustadt A., Beard R.C., Cotman C.W. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology. 21:1999;679-682.
51. Sapolsky R.M. A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults. J. Neurosci. 5:1985;1228-1232.
52. Schmued L.C., Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874:2000;123-130.
53. Seldin M.F., Surwit R.S., Ricquier D., Warden C.H. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. Genet. 15:1997;269-272.
54. Sheng P., Wang X.B., Ladenheim B., Epstein C., Cadet J.L. AP-1 DNA-binding activation by methamphetamine involves oxidative stress. Synapse. 24:1996;213-217.
55. Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J., Klenk, D.C., 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85 [erratum in: Anal. Biochem. 163, 279 (1987)].
56. Sofic E., Lange K.W., Jellinger K., Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142:1992;128-130.
57. Sonsalla P.K., Nicklas W.J., Heikkila R.E. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 243:1989;398-400.
58. Sriram K., Shankar S.K., Boyd M.R., Ravindranath V. Thiol oxidation and loss of mitochondrial complex I precede excitatory amino acid-mediated neurodegeneration. J. Neurosci. 18:1998;10287-10296.
59. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA. 76:1979;4350-4354.
60. van der Kroon P.H.W., Speijers G.J.A. Brain deviations in adult obese-hyperglycemic mice (ob/ob). Metabolism. 28:1979;1-3.
61. Wagner G.C., Ricaurte G.A., Seiden L.S., Schuster C.R., Miller R.J., Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181:1980;151-160.
62. Yang S., Zhu H., Li Y., Lin H., Gabrielson K., Trush M.A., Diehl A.M. Mitochondrial adaptations to obesity-related oxidant stress. Arch. Biochem. Biophys. 378:2000;259-268.